Status:
RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Early Alzheimer's Disease
Eligibility:
All Genders
50-85 years
Phase:
PHASE2
Brief Summary
Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memo...
Eligibility Criteria
Inclusion
- The main inclusion criteria include but are not limited to the following:
- Has mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD)
- Has a designated study partner who can fulfill the requirements of this study
- If on an approved AD therapy for symptomatic AD, the dosing regimen must have been stable for 3 months prior to screening
Exclusion
- The main exclusion criteria include but are not limited to the following:
- Has a known history of stroke or cerebrovascular disease
- Has diagnosis of a clinically relevant central nervous system disease other than AD or other condition that negatively impacts cognition or cognitive status chronically
- Has structural brain disease
- Has a history of seizures or epilepsy within 5 years before screening
- Has any other major central nervous system trauma, or infections that affect brain function
- Has major medical illness or unstable medical condition within 3 months before screening
- Has a severe, acute, or chronic medical or psychiatric condition or laboratory abnormality
- Has any immunological disease, which is not adequately controlled, or which requires treatment with biologics and/or immunosuppressants during the study
- Has a bleeding disorder that is not under adequate control
- Has a history of malignancy occurring within 5 years of screening
- Has a risk factor for corrected QT interval (QTc) prolongation
- Has liver disease
- Is unwilling or unable to undergo computed tomography (CT), positron emission tomography (PET), or magnetic resonance imaging (MRI) scan
- Resides in a nursing home or assisted care facility with need for direct continuous medical care and nursing supervision
Key Trial Info
Start Date :
July 16 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2029
Estimated Enrollment :
340 Patients enrolled
Trial Details
Trial ID
NCT07033494
Start Date
July 16 2025
End Date
April 30 2029
Last Update
March 13 2026
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
Inglewood Clinical ( Site 1062)
Inglewood, California, United States, 90301
2
Irvine Clinical Research ( Site 1041)
Irvine, California, United States, 92614
3
Healthy Brain Clinic ( Site 1005)
Long Beach, California, United States, 90804
4
Anderson Clinical Research ( Site 1024)
Redlands, California, United States, 92374